The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.08 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.87 — no flag raisedOK
- Earnings quality 85/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Pacira BioSciences, Inc. reports it. History and quarterly detail are in the app.
- Net product sales$722.9M
- EXPAREL$575.1M
- ZILRETTA$116.6M
- iovera°$24.2M
- Bupivacaine liposome injectable suspension$6.9M
Leadership changes
From Pacira BioSciences, Inc.'s own filings, the day they're filed.
- Paul J. Hastings · Directors · departureeff. 2025-01-28
- Mark Froimson Frank Lee · departureeff. 2025-01-28
- Brendan Teehan · Chief Commercial Officer · appointmenteff. 2025-01-21
Latest filings
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-30
- 8-K · Company announcement2026-02-26
- 10-K · Annual report2026-02-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Pacira BioSciences, Inc., every answer cited🔒
- The Intelligence Brief — added when Pacira BioSciences, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.